Payment overview · 2025
General Payments
$34.77
2 reported records · 2 companies
Healthcare provider profile · identity verified
Nida Maham
Allopathic & Osteopathic Physicians|Internal Medicine · ABERDEEN, SD · NPI 1689022584
Verified facts
What the public records show
CMS Open Payments records show Nida Maham received $34.77 in general payments during 2025 across 2 reported records.
Medtronic, Inc. accounted for 56.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.71 | 56.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.06 | 43.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $34.77 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 507 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 424 | 130 |
| Omeprazole | Omeprazole | 395 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 288 | 93 |
| Furosemide | Furosemide | 280 | 70 |
| Losartan Potassium | Losartan Potassium | 265 | 87 |
| Lisinopril | Lisinopril | 231 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 65 |
| Potassium Chloride | Potassium Chloride | 221 | 63 |
| Gabapentin | Gabapentin | 207 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 50 |
| Trazodone Hcl | Trazodone Hcl | 140 | 36 |
| Jardiance | Empagliflozin | 137 | 33 |
| Eliquis | Apixaban | 135 | 29 |
| Tramadol Hcl | Tramadol Hcl | 118 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 40 |
| Montelukast Sodium | Montelukast Sodium | 109 | 28 |
| Sertraline Hcl | Sertraline Hcl | 109 | 31 |
| Metformin Hcl | Metformin Hcl | 107 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 33 |
| Metformin Hcl Er | Metformin Hcl | 102 | 40 |
| Warfarin Sodium | Warfarin Sodium | 85 | 14 |
| Pregabalin | Pregabalin | 83 | 19 |
| Simvastatin | Simvastatin | 80 | 24 |
| Xarelto | Rivaroxaban | 77 | 12 |
| Allopurinol | Allopurinol | 74 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 17 |
| Sucralfate | Sucralfate | 65 | 21 |
| Ezetimibe | Ezetimibe | 64 | 24 |
| Spironolactone | Spironolactone | 64 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 24 |
| Ozempic | Semaglutide | 60 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 23 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 56 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 24 |
| Famotidine | Famotidine | 56 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 17 |
| Chlorthalidone | Chlorthalidone | 54 | 20 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 19 |
| Bumetanide | Bumetanide | 47 | 11 |
| Atenolol | Atenolol | 46 | 11 |
| Carvedilol | Carvedilol | 44 | 16 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 12 |
| Baclofen | Baclofen | 40 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 27 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Prednisone | Prednisone | 38 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | 14 |
| Finasteride | Finasteride | 33 | 11 |
| Linzess | Linaclotide | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 12 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Jantoven | Warfarin Sodium | 26 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 24 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 16 |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | 14 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 12 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 15 |
| Meloxicam | Meloxicam | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 15 |
| Dexilant | Dexlansoprazole | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Fetzima | Levomilnacipran Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34.77 · 2 records | Medtronic, Inc. | MINIMED 780G, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error